Shorten clinical development timeline using novel GPEx® Lightning technology
Speed and efficiency remain major drivers for developers advancing protein-based biologics to first-in-human studies. For 20 years, GPEx® technology has supported the generation of high expressing, highly stable mammalian cell lines with 16 commercially-approved biologics developed to date.
GPEx® Lightning further reduces development timelines and can be tailored to the specific needs of each individual program on its path to clinical trials.
Catalent will be exhibiting this year at CPHI Frankfurt 2022 on 1-3 November 2022. Come see us in person at booth #90G20.